News & Updates

Among women who are deemed high-risk for pre-eclampsia by Doppler examination, treatment with low-dose aspirin appears to have no significant clinical benefit, a recent study has found.

The use of hormone therapy poses a small but significant increase in systolic blood pressure (BP) in postmenopausal women with hypertension, a study has found. However, this BP elevation does not lead to increased BP-lowering medication use over time.

The overall efficacy and safety of tofacitinib in moderate-to-severe ulcerative colitis (UC) agree with clinical trial data, but a dose-dependent increase in adverse events (AEs) occurs, which underscores the importance of early dose de-escalation, according to a study.

Long-term use of ruxolitinib cream continued to improve facial and total body repigmentation in patients with nonsegmental vitiligo from 24 to 52 weeks, according to an updated pooled analysis of the phase III TRuE-V1* and TRuE-V2** studies presented at EADV 2022.

The oral activated factor XI (FXIa) inhibitor asundexian, when taken with aspirin plus a P2Y12 inhibitor, appears to facilitate dose-dependent, near-complete inhibition of FXIa activity with a low rate of ischaemic events and without a significant increase in bleeding, according to the results of a phase II trial.